Domestic pharma industry may face setback if US imposes tariffs

A proposed 25% US tariff on drug imports threatens India’s pharmaceutical industry, potentially disrupting the supply of affordable generics. While formulations and APIs are currently excluded, the industry faces rising compliance costs and uncertainty from ongoing investigations. Larger Indian players with US manufacturing may be insulated, but others could struggle to remain competitive.